Open AccessTherapy with bone-modifying agents in cancer patients: Efficacy versus adverse events in dental medicine
Author(s) -
Olimpia Bunta,
Iulia Najette Crintea,
Andreea Pop,
Adiemeș,
Mariana Păcurar
Publication year - 2021
Publication title -
romanian journal of stomatology
Language(s) - English
Resource type - Journals
eISSN - 2069-6078
pISSN - 1843-0805
DOI - 10.37897/rjs.2021.1.2
Subject(s) - medicine , osteonecrosis of the jaw , adverse effect , quality of life (healthcare) , bisphosphonate associated osteonecrosis of the jaw , cancer , dentistry , intensive care medicine , surgery , osteoporosis , bisphosphonate , nursing
Bone metastases affect a large number of oncological patients and can determine complications that can impact the quality of life of our patients and further translate into lessen treatment results and overall survival. Treatment with bisphosphonates (BP) has proven its efficacy in preventing the development of the complications related to bone metastases. BP are well tolerated in general but severe adverse events can occur, like osteonecrosis of the jaw (ONJ). Besides ONJ there are other dental and maxillofacial complications determined by BP, complications that by elementary preventive measures can be avoided.